My main research interests are gastrointestinal oncology, early phase clinical trials and translational research. I pioneered Hong Kong Liver Cancer classification, which has revolutionized the treatment algorithm of liver cancer patients. Moreover, I am actively involved in cancer drug development, especially in the field of caner immunotherapy. I have led few global ground-breaking immunotherapy trials for liver cancer and some of these trials led to global drug approval for advanced hepatocellular carcinoma patients. I have published more than 140 peer-review publications with first author articles in various leading oncology journals, namely Lancet, JAMA Oncology, Gastroenterology, and Journal of Hepatology. My latest H index is 49 with over 10000 citations in the literature. I am the recipient of projects funded by, Theme-based Research Scheme and General Research Fund, University Grant Committee in Hong Kong. I also received Innovation and Technology Fund and Hong Kong Health and Research Fund as well.

Internationally, I am currently the faculty member of the European Society of Medical Oncology (ESMO) in gastrointestinal cancer and a member of The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. I am also vice president of Asia Pacific Neuroendocrine Tumour Society, council member of The Asia-Pacific Primary Liver Cancer Expert (APPLE) Association and International Faculty Board Member of International Association of Surgeons Gastroenterologist and Oncologists and member of many international professional societies. Previously, I was an international member of US NCI Hepatobiliary Task Force. In Hong Kong, I am a general secretary of Hong Kong Liver Cancer Foundation and council member of Hong Kong Sustainable Council.